Centrex strong buy 0,05 noch! Bio!12%

Habe keinen akutellen Kurs?

www.biolifesolutions.com/home.htm

mal anschauen:WKN:894 679 (USA)Biolife Solutions
@lasse :habe kleines Paket geordert! Spekulativ im sinne von Marktenger Wert ,aber interessant um so mehr! Danke!

BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented under-standing of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol(R) and CryoStor(TM) products that the Company is selling today are a significant step forward in meeting these needs.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

For further information, please contact: investors, Jill Bertotti , jill@allencaron.com or media, Len Hall, len@allencaron.com , both of Allen & Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.

SOURCE BioLife Solutions Inc.



CONTACT:          investors, Jill Bertotti , jill@allencaron.com or media, Len
                 Hall, len@allencaron.com , both of Allen & Caron Inc, +1-949-474-4300, for
                 BioLife Solutions Inc.
                 (BLFS ENDO)

www.prnewswire.com

spekulatives Teil von lasse. Nicht mit Centrex zu vergleichen!

Volumen derzeit 119.300 Stk. Das ist doch gar nichts

of the target organism. This reduces the possibility of false positive and
negative test results -- common concerns frequently identified with other test
procedures.

Centrex is currently developing a fully automated, network-capable system for
detecting microbial contamination in air, food and water. The proposed device is
a simultaneous multi-channel detection system that is compact, fully automated
and capable of monitoring the presence of biological agents in air, food and
water.

Centrex was enrolled in Investrend Research's unique and pioneering professional
analyst program, which facilitates independent analysts to provide financial
coverage for shareholders and investors in companies that otherwise would have
little or no analyst following, but its coverage is presently suspended due to
the company's failure to provide access to the analyst as required by the issuer
standards of the Association for Investment Management and Research.

The Investrend Research program is the largest in the world and includes a
number of safeguards to reduce or eliminate conflict. These systems, including
media coverage and endorsements, may be accessed at
www.investrendresearch.com

Investrend Research is a member of the FIRST Research Consortium and
participates in the organization's standards development panel for independent
research providers. The "Standards for Independent Research Providers"
may be viewed at www.firstresearchconsortium.com.

The Dow Jones (NYSE: DJ) Newswires has stated that independent research has been
growing in credibility over the past 18 months, specifically citing Investrend
Research, and the New York Times (NYSE: NYT) has reported a survey by Charles
Schwab & Co. (NYSE: SCH) reveals an astonishing 78 percent of active
stockholders now "value research from independent firms over analysis by
Wall Street firms with financial ties to the companies they are rating." A
survey at Investopedia reveals that 74.7% of investors say that "legitimate
fee-based research is objective and useful," and 70.9% say that a company that
enrolls for "legitimate fee-based research is making a positive statement
about its investment potential."

Enrollment fees for Institutional coverage were $23,400, and the fees were paid
by the company. There is an open invoice for $13,700 remaining on account. There
are never any fees associated with FinancialWire, which independently covers a
wide range of corporate news, including but not limited to those that are or
have been enrolled in Investrend's platforms.

Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on
www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: www.investrend.com/XmlFeeds?level=268



URL:              www.financialwire.net


(C) 2004 financialwire.net,  Inc. All rights reserved.

gehen oder was meint ihr???

Centrex eröffnet inetwa gleich wie gestern.
Hier der Link zum Mitverfolgen wer will:
Centrex auf Yahoo

Fast 2 Mio. gehandelte Stück innerhalb von 2 Std. und +5%!!!!!

Kommt da heute moch was?

+ 22,80 % bei 2,4 Mio gehandelten Stück - jetzt gehts wieder richtung Norden

typischer verlauf von centrex  

technische Gegenbewegung meiner Meinung, obwohl die News gut waren!?

Heute haben wir mit 0,055 die 38 Tage Linie deutlich durchbrochen. Das generiert ein Kaufsignal. Bin mal gespannt, ob das nun ein Aufwärtstrend ist.

Centrex steigt in USA auf 0,075, leider mit geringem Volumen.
Hoffen wir das Beste.
Gretel  

unterstreicht ihren intakten Aufwärtstrend, den sie seit 2,5 Monaten hat!

Das zum Handelstart ist doch i.o.
Da kommt noch einiges auf uns zu

Die News waren gut, aber es könnte noch dauern? Es wird sich vorsichtig eingedeckt.

bei einem Umsatz von 250 000 Stück in Amiland kann man wohl kaum von vorsichtigem Eindecken sprechen. Das muß noch wesentlich besser werden. Ach ja, was sagt der Bauer: Durch häufiges Wiegen (Posten) nimmt die Kuh nicht zu!!!

Grüße aus Canoa Quebrada

250000 Stück ist doch ein Witz, das Volumen ist doch lächerlich! Wenn Du groß einsteigen möchtest, würdest Du über einen längeren Zeitabschnitt versuchen Dich einzudecken, um nicht selber den Kurs zu verteuern.Desweiteren würdest Du ein Teil wieder in den Markt scmeißen,um den Kurs  zu  verbilligen. Hast Du das Volumen von Calypte Bio noch in Erinnerung? Etwa gute 100Mio Aktien am Markt.
Bei etwa 95 Mio Aktien hätte der Kurs auch tiefer fallen können, aber waren regelmäßige Eindeckungen und der Kurs blieb immer recht stabil über einen langen Zeitraum.

Was meinst Du mit dem Spruch bezüglich des Bauern? Poste ich Dir zu viel bei Centrex??

oder bekommen demnächst welches..
schau mal bei wallstreet online

SMD technology, in combination with an easy-to-operate lab card device and integrated reader, is expected to be responsive to the need for rapid, user friendly and cost effective solutions for point-of-use analyses of a variety of bacterial and viral organisms. This unique technology eliminates the need for amplification of the target DNA by recognizing the unique DNA or RNA fingerprint of the target organism. This reduces the possibility of false positive and negative test results -- common concerns frequently identified with other test procedures.

Centrex is currently developing a fully automated, network-capable system for detecting microbial contamination in air, food and water. The proposed device is a simultaneous multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in air, food and water.

Centrex was enrolled in Investrend Research's unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following, but its coverage is presently suspended due to the company's failure to provide access to the analyst as required by the issuer standards of the Association for Investment Management and Research.

The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at www.investrendresearch.com

Investrend Research is a member of the FIRST Research Consortium and participates in the organization's standards development panel for independent research providers. The "Standards for Independent Research Providers" may be viewed at www.firstresearchconsortium.com.

The Dow Jones (NYSE: DJ) Newswires has stated that independent research has been growing in credibility over the past 18 months, specifically citing Investrend Research, and the New York Times (NYSE: NYT) has reported a survey by Charles Schwab & Co. (NYSE: SCH) reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential."

Enrollment fees for Institutional coverage were $23,400, and the fees were paid by the company. There is an open invoice for $13,700 remaining on account. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms.

Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: www.investrend.com/XmlFeeds?level=268




CNEX: Filed 8-K Regarding Subsidiary Formation Revocatn (Mar-02 PR)

WEDNESDAY, MARCH 03, 2004 05:04 PM

In a new 8-K filing, Centrex Inc (OTCBB: CNEX) disclosed a previous press release, originally from March 02, 2004, regarding Subsidiary Formation Revocatn.

READ COMPLETE SEC FILING FOR DETAILS




CNEX  CENTREX INC  
FALA  FIRST AMERICAN BANCORP  

--------------------------------------------------

Centrex Retains First American Financial Group

WEDNESDAY, MARCH 03, 2004 01:28 PM

TULSA, Okla., Mar 3, 2004 (BUSINESS WIRE) -- Centrex, Inc. (OTCBB:CNEX) today announced that FIRST AMERICAN FINANCIAL GROUP, a private equity firm with offices in New York, has been retained to act as a financial consultant for the Company. Centrex has signed a term sheet with FIRST AMERICAN for up to $3.5 million in funding which includes an initial bridge loan of $500,000. The financing is contingent upon entering into definitive documentation. FIRST AMERICAN is a boutique Financial Services firm specializing in procuring capital for emerging growth small-cap and micro-cap companies.

"We are pleased to be associated with Centrex, a company that is in the process of developing a technology to provide for the immediate detection of agents that could be used in bioterrorism or biowarfare against the U.S.," stated Bill Rogers, Managing Director of FIRST AMERICAN.

Centrex owns the exclusive worldwide license to develop, manufacture and market the Single Molecule Nucleic Acid Detection (SMD) technology developed at Los Alamos National Laboratories. SMD offers important advantages over existing DNA and RNA detection methods as well as culture-based test methods for the detection and identification of bacteria and viruses.

SMD technology, in combination with an easy-to-operate lab card device and integrated reader, is expected to be responsive to the need for rapid, user friendly and cost effective solutions for point-of-use analyses of a variety of bacterial and viral organisms. This unique technology eliminates the need for amplification of the target DNA by recognizing the unique DNA or RNA fingerprint of the target organism. This reduces the possibility of false positive and negative test results -- common concerns frequently identified with other test procedures.

Centrex is currently developing a fully automated, network-capable system for detecting microbial contamination in air, food and water. The proposed device is a simultaneous multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in air, food and water.

This press release contains certain forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings.

SOURCE: Centrex, Inc.